Table 1.

Patients' Characteristics.

Patient No.	Age (years)	Menopausal Status	MR Tumor Dimensions (AP x ML x SI; cm)	Histologic Diagnosis	Grade	ER/PR	Her-2-neu	Residual In Situ Size (%)	Neoadjuvant Treatment
1	47	Premenopausal	5 x 4.5 x 4.5	Lobular	2	+	-	70	Chemoradiotherapy
2	38	Premenopausal	11.2 x 7.3 x 8.3	Ductal	3	+	+	0	Sunitinib, trastuzumab → docetaxel, trastuzumab, pamidronate
3	54	Postmenopausal	6.1 x 7.8 x 3.3	Ductal	2	-	-	5–10	Epirubicin, docetaxel
4	61	Postmenopausal	10 x 6	Ductal	2	-	-	30	Chemoradiotherapy
5	56	Postmenopausal	11 x 6.3 x 5.5	Ductal	2	+	-	5–10	Epirubicin, docetaxel
6	48	Premenopausal	7.8 x 4.6 x 5.5	Ductal	2	-	+	>80	AC + paclitaxel, trastuzumab
7	64	Postmenopausal	7.5 x 6.5 x 5.5	Ductal	2	+	-	5–10	AC + paclitaxel, trastuzumab
8	45	Premenopausal	5.1 x 5.5 x 4.5	Ductal	2	+	+	>90	Chemoradiotherapy
9	47	Premenopausal	4.8 x 3.1 x 5.5	Ductal	2	+	+	60	Docetaxel, carboplatinum, trastuzumab
10	57	Postmenopausal	10.2 x 7.2 x 6.8	Lobular	1	+	+	5–10	FEC + docetaxel
11	43	Premenopausal	6.6 x 3.7 x 7.9	Ductal	2	+	-	85	FEC + docetaxel
12	56	Postmenopausal	2.4 x 2.7 x 3.2	Ductal	2	-	+	0	AC + paclitaxel, trastuzumab
13	49	Premenopausal	2.4 x 2.8 x 1.4 and 1.4 x 2.8 x 1.3	Ductal	2	-	+	>90	AC + paclitaxel, trastuzumab
14	38	Premenopausal	9 x 6.6 x 6	Ductal	2	+	-	60	AC + paclitaxel
15	36	Premenopausal	12 x 11.6 x 8.9	Ductal	1	+	-	20	AC + paclitaxel

AC indicates adriamycin and cytoxan; FEC, fluorouracil (5-FU), epirubicin and cyclophosphamide.